Defective regulatory B-cell compartment in patients with immune thrombocytopenia

Blood

Volumn 120, Issue 16, 2012, Pages 3318-3325

  Li, Xiaojuan ^a,b   Zhong, Hui ^a   Bao, Weili ^a   Boulad, Nayla ^c   Evangelista, Jessie ^c   Haider, Muhammad Anis ^c   Bussel, James ^c   Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOREGULATION; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

EID: 84868100092     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-432575     Document Type: Article

References (43)

1. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944-950. (Pubitemid 35154008)
2. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med. 2000;192(4):475-482. (Pubitemid 30666248)
3. Blair PA, Norena LY, Flores-Borja F, et al. CD19 (+) CD24 (hi) CD38 (hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32(1):129-140.
4. Bouaziz JD, Calbo S, Maho-Vaillant M, et al. IL-10 produced by activated human B cells regulates CD4 (+) T-cell activation in vitro. Eur J Immunol. 2010;40(10):2686-2691.
5. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530-541.
6. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1836-1847.
7. Mauri C, Bosma A. Immune regulatory function of B cells. Ann Rev Immunol. 2012;30:221-41.
8. Carter NA, Vasconcellos R, Rosser EC, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011;186(10):5569-5579.
9. Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 2010;125(5):1114-1124.
10. Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist. 2009;14(1):12-21.
11. Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009;114(26):5362-5367.
12. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136(2):309-314. (Pubitemid 46020761)
13. Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27 (+) IgM (-) IgD (-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99(5):1544-1551. (Pubitemid 34533024)
14. Liu XG, Ma SH, Sun JZ, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117(6):2061-2069.
15. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991;78(10):2619-2625.
16. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245-4254. (Pubitemid 26152268)
17. Ogawara H, Handa H, Morita K, et al. High Th1 Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;71(4):283-288. (Pubitemid 37174699)
18. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of antiplatelet autoantibody. J Clin Invest. 1998;102(7):1393-1402. (Pubitemid 28467568)
19. Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001;98(1):130-139.
20. Sakakura M, Wada H, Tawara I, et al. Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120(2):187-193. (Pubitemid 46754414)
21. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4 (+) CD25 (+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;789(2):139-143. (Pubitemid 46058876)
22. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79(4):310-316. (Pubitemid 47390130)
23. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B celldepleting therapy with rituximab. Blood. 2008;112(4):1147-1150.
24. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112(4):1325-1328.
25. Audia S, Samson M, Guy J, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118(16):4394-4400.
26. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672-1681. (Pubitemid 44583957)
27. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237- 2247. (Pubitemid 350190754)
28. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-2171.
29. Bussel JB. Update on eltrombopag for ITP. Oncology. 2009;23(13):1177- 1178.
30. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403. (Pubitemid 351181334)
31. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889-1899.
32. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639-4645.
33. Martinez-Gamboa L, Mei H, Loddenkemper C, et al. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol. 2009;1309(2):199-212.
34. Wasserstrom H, Bussel J, Lim LC, Cunningham-Rundles C. Memory B cells and pneumococcal antibody after splenectomy. J Immunol. 2008;181(5):3684-3689.
35. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood. 2005;105(1):215-218. (Pubitemid 40053085)
36. May AE, Kalsch T, Massberg S, et al. Engagement of glycoprotein IIb/IIIa (alpha (IIb) beta3) on platelets upregulates CD40L and triggers CD40Ldependent matrix degradation by endothelial cells. Circulation. 2002;106(16):2111-2117. (Pubitemid 35192818)
37. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol. 2001;167(7):3610-3618. (Pubitemid 32916053)
38. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol. 2001;167(4):2361-2369. (Pubitemid 32747551)
39. Liu YJ, Banchereau J. Regulation of B-cell commitment to plasma cells or to memory B cells. Semin Immunol. 1997;99(4):235-240. (Pubitemid 27331992)
40. Fogarty PF, Rick ME, Zeng W, Risitano AM, Dunbar CE, Bussel JB. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol. 2003;133(3):461-466. (Pubitemid 37046973)
41. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):326-337.
42. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924-2930. (Pubitemid 350006946)
43. Kessel A, Haj T, Peri R, et al. Human CD19 (+) CD25 (high) B regulatory cells suppress proliferation of CD4 (+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2012;11(9):670-677.